Evotec SE (EVO) Non-Current Deffered Revenue (2009 - 2022)
Evotec SE's (EVO) quarterly Non-Current Deffered Revenue came in at -$205.8 million in Q2 2022, down 437.39% quarter-over-quarter from -$38.3 million in Q4 2021.
Powered by 
Analysis
Evotec SE (EVO) Non-Current Deffered Revenue (2009 - 2022) Analysis & Trends
Evotec SE has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting -$205.8 million for Q2 2022.
- In Q2 2022, Non-Current Deffered Revenue changed N/A year-over-year to -$205.8 million; the TTM figure through Jun 2022 stood at -$205.8 million (changed N/A YoY), while the FY2021 annual figure was -$39.6 million, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at -$205.8 million for Q2 2022 at Evotec SE, down from -$38.3 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of -$38.3 million in Q4 2021 to a low of -$205.8 million in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | - |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | - |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | - |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | 158.90 Mn |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 76.54 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -205.80 Mn |
| Dec 31, 2021 | -38.30 Mn |
| Sep 30, 2010 | 1.60 Mn |
| Jun 30, 2010 | 483,163.42 |
| Mar 31, 2010 | 1,566.11 |
| Dec 31, 2009 | 2.91 Mn |
| Mar 31, 2009 | 689,175.59 |